Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 4/2019

01-10-2019 | Stem Cell Transplantion | Short Communication

Tacrolimus Induced Diabetic Ketoacidosis Following Hematopoietic Stem Cell Transplantation

Authors: Sanjeev Kumar Sharma, Divya Doval, Vipin Khandelwal, Meet Kumar, Dharma Choudhary

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 4/2019

Login to get access

Abstract

Risk of diabetes mellitus increases after solid organ and hematopoietic stem cell transplantation. Diabetic ketoacidosis has been reported after solid organ transplantation in patients receiving tacrolimus but has rarely been reported after stem cell transplantation. The major risk factors for diabetic ketoacidosis are immunosuppressive drugs used after transplantation. We report here three cases of allogenic stem cell transplant who developed diabetic ketoacidosis while on treatment with tacrolimus. The drug was stopped in all the cases and patients were treated with insulin therapy resulting in complete recovery from diabetic ketoacidosis.
Literature
1.
Fortune K, Couriel D (2009) Tacrolimus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 5(7):835–841CrossRef
2.
Koehler MT, Howrie D, Mirro J, Neudorf S et al (1995) FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 15(6):895–899PubMed
3.
Kramer BK, Montagnino G, Castillo D et al (2005) Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transpl 20:968–973CrossRef
4.
Salvadori M, Bertoni E, Rosati A, Zanazzi M (2003) Post-transplant diabetes mellitus. J Nephrol 16(5):626–634PubMed
5.
Greenspan LC, Gitelman SE, Leung MA et al (2002) Increased incidence in post-transplant diabetes mellitus in children: a case control analysis. Pediatr Nephrol 17:1–5CrossRef
6.
Traggiai C, Stanhope R, Nussey S, Leiper AD (2002) Diabetes mellitus after bone marrow transplantation during childhood. Med Pediatr Oncol 40:128–129CrossRef
7.
Griffith ML, Jagasia M, Jagasia SM (2010) Diabetes mellitus after hematopoietic stem cell transplantation. Endocr Pract 16(4):699–706CrossRef
8.
Solmaz S, Gökgöz Z, Gereklioğlu C et al (2017) Tacrolimus-induced diabetic ketoacidosis after allogeneic bone marrow transplant. Exp Clin Transpl 15(6):702–703
9.
Ricordi C, Zeng Y, Alezandro R et al (1991) In vivo effect of FK506 on human pancreatic islets. Transplantation 52:519–522CrossRef
10.
Duijnhoven EM, Boots JM, Christiaans MH et al (2001) Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. JASN 12:583–588PubMed
11.
Jindal RM, Sidner RA, Milgrom ML (1997) Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 16(4):242–257CrossRef
12.
Yoshida EM, Buczkowski AK, Sirrs SM, Elliott TG et al (2000) Post-transplant diabetic ketoacidosis—a possible consequence of immunosuppression with calcineurin inhibiting agents: a case series. Transpl Int 13:69–72CrossRef
13.
Montori VM, Basu A, Erwin PJ et al (2002) Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25(3):583–592CrossRef
14.
Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245CrossRef
Metadata
Title
Tacrolimus Induced Diabetic Ketoacidosis Following Hematopoietic Stem Cell Transplantation
Authors
Sanjeev Kumar Sharma
Divya Doval
Vipin Khandelwal
Meet Kumar
Dharma Choudhary
Publication date
01-10-2019
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2019
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01113-w

Other articles of this Issue 4/2019

Indian Journal of Hematology and Blood Transfusion 4/2019 Go to the issue

Erratum

Erratum to: Abstracts of the Oral and Poster Presentations During Haematocon 2015 (56th Annual Conference of Indian Society of Haematology & Blood Transfusion)

Original Article

Impact Analysis of the National Guidelines for Blood Donor Selection in India: A Single Center Study

Editorial

An Editor-in-Chief’s Reminiscences

Original Article

Effect of Frequency of Platelet Apheresis on Coagulation Function in Donors: A Prospective Cohort Study

Original Article

Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia

Short Communication

Magical Myth of Magic Mouth Wash
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits